NASDAQ$MGNX
MacroGenics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the quarter ended March 31, 2022 and provided update on corporate progress.
MacroGenics reported first quarter 2022 financial results, with total revenue of $11.1 million, including $3.6 million in MARGENZA sales. The company's net loss was $66.4 million. They plan to start Phase 2/3 prostate cancer study with MGC018 by year-end and initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors.
- Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end.
- Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors.
- Targeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignancies.
- FDA accepted the Biologics License Application (BLA) for teplizumab for the delay of clinical T1D in at-risk individuals.
Headline financials
Revenue & EPS history
MacroGenics · Revenue · Quarterly
$11.1M
Revenue by segment
MacroGenics · $7.52M total across 2 segments · Q1 2022
- Collaborative Agreements$7.09M-53.3%94.3%
- Government Agreements$428K-47.2%5.7%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+5.6%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+3.4%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+251.7%
Q1 2020
Best reaction
-77.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | +24.0% | +12.9% | |
| Q4 2025 | +45.3% | +27.1% | +45.8% | |
| Q3 2025 | +8.3% | +4.8% | -4.8% | |
| Q1 2025 | +0.0% | +0.0% | -5.1% | |
| Q4 2024 | -4.8% | -25.7% | -40.0% | |
| Q3 2024 | +13.2% | +17.6% | -8.4% | |
| Q2 2024 | -5.6% | -1.7% | -5.6% | |
| Q1 2024 | -77.4% | -69.6% | -69.1% | |
| Q4 2023 | -18.8% | -18.0% | -15.0% | |
| Q3 2023 | +20.0% | +20.5% | +62.7% | |
| Q2 2023 | +26.6% | +13.7% | +4.7% | |
| Q1 2023 | -0.4% | -9.1% | -28.2% | |
| Q4 2022 | +8.4% | +3.7% | +0.6% | |
| Q3 2022 | +22.1% | +30.1% | +42.3% | |
| Q2 2022 | +16.2% | +18.9% | -3.6% | |
| Q1 2022 | -15.2% | -38.2% | -56.5% | |
| Q4 2021 | -3.6% | -8.1% | -12.7% | |
| Q3 2021 | +4.1% | +5.1% | -16.7% | |
| Q2 2021 | -5.5% | -5.7% | -10.3% | |
| Q1 2021 | -8.3% | -9.8% | -8.8% | |
| Q4 2020 | +18.7% | +16.1% | +57.6% | |
| Q3 2020 | +4.9% | +0.9% | +19.9% | |
| Q2 2020 | -1.5% | +3.1% | +5.9% | |
| Q1 2020 | +251.7% | +184.5% | +186.4% | |
| Q4 2019 | +8.5% | -20.8% | -45.5% | |
| Q3 2019 | -0.9% | -6.5% | +13.9% | |
| Q2 2019 | -0.3% | -9.1% | -2.5% | |
| Q1 2019 | +3.4% | +9.7% | +9.4% | |
| Q4 2018 | -2.8% | -5.8% | -19.4% | |
| Q3 2018 | +8.7% | -1.0% | -2.3% | |
| Q2 2018 | +6.3% | +9.5% | +11.1% | |
| Q1 2018 | -9.2% | -7.8% | +2.8% | |
| Q4 2017 | +2.1% | +17.7% | +2.4% | |
| Q3 2017 | -1.6% | -0.3% | +8.9% | |
| Q2 2017 | +6.6% | +8.0% | +17.8% | |
| Q1 2017 | -1.7% | -12.2% | -9.9% | |
| Q4 2016 | -5.1% | -2.7% | -15.8% | |
| Q3 2016 | -16.3% | -6.0% | +10.4% | |
| Q2 2016 | +6.8% | +1.1% | -2.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +5.1% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -12.1% | — | — | |
| Q1 2015 | +9.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | +17.5% | — | — | |
| Q2 2014 | -4.8% | — | — | |
| Q2 2013 | -4.8% | — | — | |
| Q1 2014 | -5.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2013 | -7.6% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro